We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+70.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$379M
AUM Growth
+$1.99M
(+0.53%)
Cap. Flow
-$143M
Cap. Flow
% of AUM
-37.85%
Top 10 Holdings %
Top 10 Hldgs %
49.33%
Holding
57
New
10
Increased
10
Reduced
18
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$7.92M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$7.56M |
| 3 |
TG Therapeutics
TGTX
|
+$6.44M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$5.32M |
| 5 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$5.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$18.8M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
+$13.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$11.7M |
| 4 |
Axsome Therapeutics
AXSM
|
+$8.85M |
| 5 |
ADVM
Adverum Biotechnologies
ADVM
|
+$7.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Verastem
VSTM
$530M
| – | – |
-125,000
| Closed | -$3.96M |
|
52
CALL
State Street Health Care Select Sector SPDR ETF
XLV
$41.4B
| – | – |
-244,700
| Closed | -$21.7M |
|
|
ORTX
53
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| – | – |
-17,811
| Closed | -$1.34M |
|
|
AGTC
54
DELISTED
Applied Genetic Technologies Corporation
AGTC
| – | – |
-372,806
| Closed | -$1.22M |
|
|
PHAS
55
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| – | – |
-497,074
| Closed | -$1.65M |
|
|
KDMN
56
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-350,000
| Closed | -$1.47M |
|
|
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-150,000
| Closed | -$3.71M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q2 2020 Portfolio in Review
As of Q2 2020, Ghost Tree Capital held 57 positions worth $379M, up 0.53% from $377M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital withdrew a net $143M in Q2 2020, closing 14 positions and reducing 18 holdings. Its most notable exit was Verastem, an estimated $3.96M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 54% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in Acadia Pharmaceuticals worth $8M.
- Ghost Tree Capital's largest Q2 2020 buy was Acadia Pharmaceuticals: 165,000 shares worth $8M.
- Ghost Tree Capital added most to Iovance Biotherapeutics in Q2 2020, an estimated $7.56M increase.
- Ghost Tree Capital's biggest Q2 2020 reduction was Mersana Therapeutics, cutting an estimated $18.8M.
- Ghost Tree Capital fully exited Verastem in Q2 2020, selling an estimated $3.96M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $379M portfolio in Q2 2020.
- Ghost Tree Capital opened 10 new positions and closed 14 in Q2 2020.
- Ghost Tree Capital's portfolio value rose 0.53% quarter-over-quarter to $379M.
Based on Ghost Tree Capital's 13F filing for Q2 2020, filed 14 Aug 2020.